{"id":62325,"date":"2025-12-09T10:05:46","date_gmt":"2025-12-09T09:05:46","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/worlds-first-patients-successfully-treated-with-novel-scarcell-therapeutics-therapy-using-gum-cells-designed-to-relieve-knee-osteoarthritis\/"},"modified":"2025-12-09T10:05:46","modified_gmt":"2025-12-09T09:05:46","slug":"worlds-first-patients-successfully-treated-with-novel-scarcell-therapeutics-therapy-using-gum-cells-designed-to-relieve-knee-osteoarthritis","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/worlds-first-patients-successfully-treated-with-novel-scarcell-therapeutics-therapy-using-gum-cells-designed-to-relieve-knee-osteoarthritis\/","title":{"rendered":"World\u2019s First Patients Successfully Treated With Novel Scarcell Therapeutics Therapy Using Gum Cells Designed to Relieve Knee Osteoarthritis"},"content":{"rendered":"
\n

\nScarcell\u2019s Allogenic Gingival Fibroblast (aGF) Therapy First Long-Lasting Osteoarthritis Treatment to Target All Four Major Disease Effects<\/b>\n<\/p>\n

\nFirst-Ever Use of Donor Gum Cells to Treat Osteoarthritis in Humans<\/b>\n<\/p>\n

PARIS–(BUSINESS WIRE)–#arthritis<\/a>—Scarcell Therapeutics<\/a>, an innovator in cell therapies to treat chronic degenerative inflammatory diseases, today announced the world\u2019s first patients treated with its Allogenic Gingival Fibroblast (aGF) Therapy<\/a> using gum cells from a human donor as part of its Phase Ib clinical trial studying the therapy in knee osteoarthritis (OA). The first-in-human cases took place at Oxford University Hospitals, UK, and were led by Dr. Alex Shearman and Dr. Antony Palmer, orthopedic surgeons and principal and co-investigator of the study, respectively, and Dr. Rajat Chowdhury, a musculoskeletal radiologist who performed the intra-articular cell injection of the knee.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\nOA is a complex, degenerative and incurable disease, involving multiple joint tissues and pain mechanisms. Scarcell\u2019s patented aGF Therapy is uniquely designed to address all four of the major effects of OA \u2013 cartilage degeneration, joint inflammation, mobility and pain \u2013 in a single injection intended to be durable for up to one year. There is currently no commercial pharmaceutical or developmental cell therapy targeting all four effects.\n<\/p>\n

\n\u201cWe are excited to lead research into this novel cell therapy for early OA, in an effort to address the unmet needs of many patients whose symptoms can be debilitating,\u201d said Dr. Shearman. \u201cThe commencement of this trial is the result of a successful collaboration between orthopedic surgeons, radiologists, specialist pharmacy and clinical research teams.\u201d\n<\/p>\n

\nThe Phase Ib clinical trial is studying a single intra-articular injection of aGF Therapy in 15 patients treated at Oxford University Hospital. The study will examine safety, as well as knee pain, inflammation and analgesic use.\n<\/p>\n

\nScarcell\u2019s aGF Therapy is designed to exhibit four mechanisms of action (MOA):\n<\/p>\n